This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021.

Speakers

Rafick_Sekaly.png

Rafick Sekaly

Professor of Pathology
Case Western Reserve University
USA

RAFICK-PIERRE SEKALY, PH.D, Case Western Reserve University, School of Medicine Department of Pathology.

Dr. Sekaly is the Richard J. Fasenmyer Professor of Immunopathogenesis. His research group has been continuously funded since 1988 by federal and nonfederal grants. He is the principal investigator on numerous grants from the National Institutes of Health, the Bill and Melinda Gates Foundation, the American Foundation for AIDS Research, the Fred Hutchinson Cancer Research Center, Gilead Sciences Incorporation, Merck Sharp & Dohme Corporation, and more.

Dr. Sekaly is Co-Director of the Center of Systems Immunology (CSI), and Codirector of the Center for AIDS Research (CFAR) Proteomics and Systems Biology Core at Case Western Reserve University. His focus on HIV disease immune pathogenesis, immune virology, and immunotherapies has generated pioneering findings that highlight the impact of HIV infection on thymic output, T cell memory, mechanisms of CD4 and CD8 T cell dysfunction, and on innate immunity and mechanisms of HIV persistence.

He has also pioneered the use of transcriptomics and bioinformatics to identify predictors/correlates of immune responses that lead to protection from viral infections, including HIV, SIV and flaviviruses, protection from disease progression and successful immune interventions including adjuvants, licensed preventative and therapeutic vaccines. Dr. Sekaly’s efforts resulted in novel approaches to cancer and HIV vaccines and have led to more than 340 peer-reviewed articles in scientific journals and 25 patents in Adjuvants, PD-1 and vaccine vectors.